Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea
· Delayed Price · Currency is KRW 235,500
+1,000 (0.43%)
At close: Apr 17, 2025, 3:30 PM KST
Hanmi Pharm. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Other Revenue | - | - | -0 | - | -0 | Upgrade
|
| Revenue | 1,495,502 | 1,490,887 | 1,331,547 | 1,203,186 | 1,075,854 | Upgrade
|
| Revenue Growth (YoY) | 0.31% | 11.97% | 10.67% | 11.83% | -3.39% | Upgrade
|
| Cost of Revenue | 678,465 | 661,638 | 612,994 | 570,433 | 494,935 | Upgrade
|
| Gross Profit | 817,037 | 829,249 | 718,553 | 632,752 | 580,918 | Upgrade
|
| Selling, General & Admin | 421,960 | 426,789 | 406,146 | 361,309 | 319,555 | Upgrade
|
| Research & Development | 178,891 | 181,769 | 154,317 | 146,027 | 212,387 | Upgrade
|
| Operating Expenses | 604,526 | 604,364 | 564,657 | 507,336 | 531,942 | Upgrade
|
| Operating Income | 212,511 | 224,885 | 153,896 | 125,416 | 48,976 | Upgrade
|
| Interest Expense | -24,374 | -28,508 | -22,647 | -16,577 | -24,867 | Upgrade
|
| Interest & Investment Income | 5,666 | 4,618 | 7,856 | 5,722 | 4,380 | Upgrade
|
| Earnings From Equity Investments | -9.2 | 1,258 | -8,537 | -4.02 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 9,318 | 1,039 | -2,641 | 13.07 | 3,461 | Upgrade
|
| Other Non Operating Income (Expenses) | -29,309 | -4,571 | -3,620 | -9,277 | -5,462 | Upgrade
|
| EBT Excluding Unusual Items | 173,802 | 198,721 | 124,308 | 105,293 | 26,488 | Upgrade
|
| Gain (Loss) on Sale of Investments | -87.92 | 2,630 | 47.09 | - | -4,514 | Upgrade
|
| Gain (Loss) on Sale of Assets | 27.74 | 1,769 | 451.65 | -1,062 | -313.72 | Upgrade
|
| Asset Writedown | -2,488 | -9,153 | -3,794 | -535.2 | 470.68 | Upgrade
|
| Pretax Income | 171,254 | 193,967 | 121,013 | 103,697 | 22,130 | Upgrade
|
| Income Tax Expense | 30,823 | 28,601 | 19,454 | 22,218 | 4,841 | Upgrade
|
| Earnings From Continuing Operations | 140,431 | 165,366 | 101,558 | 81,478 | 17,290 | Upgrade
|
| Minority Interest in Earnings | -19,116 | -19,135 | -18,766 | -14,453 | -5,330 | Upgrade
|
| Net Income | 121,315 | 146,231 | 82,792 | 67,025 | 11,959 | Upgrade
|
| Net Income to Common | 121,315 | 146,231 | 82,792 | 67,025 | 11,959 | Upgrade
|
| Net Income Growth | -17.04% | 76.63% | 23.52% | 460.45% | -77.05% | Upgrade
|
| Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | Upgrade
|
| Shares Change (YoY) | -0.08% | -0.09% | -0.12% | -0.11% | -0.09% | Upgrade
|
| EPS (Basic) | 9566.83 | 11522.12 | 6517.33 | 5269.87 | 939.25 | Upgrade
|
| EPS (Diluted) | 9566.83 | 11522.12 | 6517.33 | 5269.87 | 939.25 | Upgrade
|
| EPS Growth | -16.97% | 76.79% | 23.67% | 461.07% | -77.03% | Upgrade
|
| Free Cash Flow | 154,226 | 189,186 | 131,890 | 181,974 | 109,719 | Upgrade
|
| Free Cash Flow Per Share | 12162.13 | 14906.67 | 10382.37 | 14307.73 | 8617.07 | Upgrade
|
| Gross Margin | 54.63% | 55.62% | 53.96% | 52.59% | 54.00% | Upgrade
|
| Operating Margin | 14.21% | 15.08% | 11.56% | 10.42% | 4.55% | Upgrade
|
| Profit Margin | 8.11% | 9.81% | 6.22% | 5.57% | 1.11% | Upgrade
|
| Free Cash Flow Margin | 10.31% | 12.69% | 9.90% | 15.12% | 10.20% | Upgrade
|
| EBITDA | 309,842 | 323,339 | 250,738 | 214,502 | 110,315 | Upgrade
|
| EBITDA Margin | 20.72% | 21.69% | 18.83% | 17.83% | 10.25% | Upgrade
|
| D&A For EBITDA | 97,331 | 98,454 | 96,842 | 89,086 | 61,339 | Upgrade
|
| EBIT | 212,511 | 224,885 | 153,896 | 125,416 | 48,976 | Upgrade
|
| EBIT Margin | 14.21% | 15.08% | 11.56% | 10.42% | 4.55% | Upgrade
|
| Effective Tax Rate | 18.00% | 14.74% | 16.08% | 21.43% | 21.87% | Upgrade
|
| Advertising Expenses | 78,789 | 76,034 | 72,627 | 62,201 | 58,772 | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.